## Pfizer Continues Development of Twice-Daily Weight Loss Drug Danuglipron
Pfizer, one of the three pharmaceutical companies competing in the weight loss drug race, has decided to continue the development of its twice-daily weight loss drug danuglipron. This decision comes after the company scrapped its once-daily drug lotiglipron due to concerns over liver damage. Yahoo Finance Health Care Reporter Anjalee Khemlani breaks down the story in a recent video transcript.
### The Details
– Pfizer’s pill for weight loss or Type 2 diabetes falls under the GLP 1 class of drugs.
– The company decided to pick one of their candidates that is a twice daily pill rather than the once daily, which was what investors and those watching the space closely had expected.
– Novo Nordisk already has its market contender on the market for Type 2 approved, while Eli Lilly has one pill option geared towards obesity.
– Pfizer’s decision to scrap lotiglipron represents a clear setback to the program, with this specific candidate expected to be the more competitive of the two assets that Pfizer had.
– Pfizer is still working through the phase two program for danuglipron, while Eli Lilly is a little bit ahead with some news out last week on positive indications from its pill.
– Pfizer is also working on trying to get this twice daily pill into a once daily format.
### The Impact
Pfizer’s decision to continue the development of danuglipron is a significant move in the weight loss drug race. However, the company’s setback with lotiglipron has caused a hit to its stock. The competition in this space is fierce, with Novo Nordisk and Eli Lilly already having products on the market. Pfizer will need to work quickly to catch up and make danuglipron a viable contender.
The weight loss drug race is heating up, and Pfizer’s decision to continue the development of danuglipron is a significant move. However, the company’s setback with lotiglipron has caused a hit to its stock. Pfizer will need to work quickly to catch up and make danuglipron a viable contender in the market.